Clinical trials: Gastrointestinal Irritation
Irritable Bowel Syndrome
Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain
This study will explore the safety and effectiveness of different doses of AGN 203818 in relieving Irritable Bowel Syndrome pain. The study is being conducted in 2 parts.
- Trial name
- NCT00441766
- Testing
- AGN 203818
- Where
- United States
- Volunteers
- 213 people
- Sponsor
- Allergan
Irritable Bowel Syndrome
Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome
To assess the effectiveness of alverine citrate and simeticone on IBS symptoms according to the latest recommended design
- Trial name
- NCT00542295
- Testing
- alverine citrate and simeticone
- Where
- 18 sites in Hungary, Poland
- Volunteers
- 400 people
- Sponsor
- Laboratoires Mayoly Spindler
Irritable Bowel Disease
Assessing Uniqueness of Inflammatory Bowel Disease Related Microbiome-derived Biomarkers
To assess the differential expression of IBD-related microbiome-derived biomarkers including bacterial strains and peptides such as antimicrobial peptides (AMP) found in inner-colonic samples (HygiSample™) in comparison to home…
- Trial name
- NCT05640583
- Testing
- Hygieacare System
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- HyGIeaCare, Inc.
NSAID Related Gastric Irritation
Pilot Study of OXP001 and Brufen in Healthy Subjects
Oxford Pharmascience (the sponsor) is developing a new formulation of Ibuprofen (OXP001 - the study drug) which it is proposed will have less of the side effects than are currently reported with standard prescription strength…
- Trial name
- NCT02050958
- Testing
- OXP001, Ibuprofen
- Where
- United Kingdom
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Oxford Pharmascience Ltd
Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Effect of a Probiotic Formula on Reducing SIBO in IBS Patients
This randomized study evaluates the effectiveness of the a probiotic formula, compared with the antibiotic rifaximin, in the treatment of Small Intestinal Bacterial Overgrowth (SIBO) in Irritable Bowel Syndrome (IBS) patients.
- Trial name
- NCT04316806
- Testing
- Probiotic, Rifaximin
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- AB Biotics, SA
Diarrhea-predominant Irritable Bowel Syndrome
Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
This study is being conducted to evaluate in participants with diarrhea-predominant Irritable Bowel Syndrome (IBS-D) the abdominal pain response to BOS-589 after 4 weeks of treatment and to evaluate the overall safety and…
- Trial name
- NCT03977155
- Testing
- BOS-589
- Where
- 58 sites in United States
- Volunteers
- 133 people
- Sponsor
- Boston Pharmaceuticals
IBS - Irritable Bowel Syndrome
Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS)
A three month follow-up study to evaluate the effectiveness of a tailored anti-inflammatory eating plan guided by a registered dietitian to treat irritable bowel syndrome.
- Trial name
- NCT05178017
- Testing
- Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Oxford Biomedical Technologies, Inc.
IBS - Irritable Bowel Syndrome, Inflammation
Study of Inflammatory Markers and Symptom Severity in Personalized Nutritional Intervention in IBS
Irritable Bowel Syndrome (IBS) is a widespread disease with variable symptoms that have an important impact on the quality of life.
- Trial name
- NCT04348760
- Testing
- Rotation Diet
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- GEK Srl
Irritable Bowel Syndrome With Diarrhea
Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).
The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients.
- Trial name
- NCT06153420
- Testing
- CIN-103
- Where
- 53 sites in United States
- Volunteers
- 421 people
- Sponsor
- CinPhloro Pharma, LLC
IBS - Irritable Bowel Syndrome
Effects of a Combination of Polyphenol-rich Extracts, Prebiotics, and Hydrolyzed Fiber on the Quality of Life of Patients With Irritable Bowel Syndrome (IBS)
The aim of the study is to demonstrate a beneficial effect in reducing symptoms that negatively affect the quality of life of IBS patients, and to demonstrate a positive effect on inflammatory and intestinal function markers.
- Trial name
- NCT05990764
- Testing
- Probiotic, Prebiotic, Polyphenol-rich Extracts, Probiotic, Prebiotic
- Where
- Poland
- Volunteers
- 48 people
- Sponsor
- AronPharma Sp. z o. o.
Irritable Bowel Syndrome
A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers
This FTIH study is designed to assess the safety, tolerability and pharmacokinetic (PK) of escalating single and repeat oral doses of GSK3352589 in normal healthy volunteers.
- Trial name
- NCT03154086
- Testing
- GSK3352589
- Where
- Australia
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome With Diarrhea
12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea.
- Trial name
- IRIS-05 (NCT02320318)
- Testing
- Ibodutant 10 mg
- Where
- 20 sites in Singapore, South Korea and 1 more
- Sponsor
- Menarini Group
Irritable Bowel Syndrome, Colonic Diseases
A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome
This study is designed to evaluate the safety and effectiveness of an investigational drug, TRN-002 (crofelemer) to relieve the symptoms of diarrhea-predominant irritable bowel syndrome (IBS).
- Conditions
- Irritable Bowel Syndrome, Colonic Diseases, Diarrhea, Gastrointestinal Disease
- Trial name
- NCT00101725
- Testing
- crofelemer
- Where
- 29 sites in United States
- Volunteers
- 245 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Colon, Irritable Bowel Syndrome (IBS)
Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
The purpose of this study is to compare the safety and effectiveness of different doses of an investigational medication in women with severe diarrhea-predominant Irritable Bowel Syndrome (IBS) who have failed conventional…
- Trial name
- NCT00067561
- Testing
- Alosetron
- Where
- 178 sites in United States, Australia
- Volunteers
- 702 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome
Phase I Clinical Trial of DA-6886 in Healthy Male Subjects
DA-6886_IBS_I is a phase I, dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose escalation clinical trial with open-labelled food effect study of single dose to investigate the safety…
- Trial name
- NCT01633723
- Testing
- DA-6886
- Where
- South Korea
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Irritable Bowel Syndrome With Diarrhea (IBS-D)
A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
To evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of MD-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
- Trial name
- NCT03931785
- Testing
- MD-7246
- Where
- 80 sites in United States
- Volunteers
- 515 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome, Gallstone Disease
Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.
This study aims to evaluate pharmacokinetic profile, safety and establish bioequivalence of the investigational drug Trimedat® 76,95 mg orally disintegrating tablets compared to the reference drug Trimedat® 100 mg tablets in…
- Conditions
- Irritable Bowel Syndrome, Gallstone Disease, GERD, Biliary Dyskinesia
- Trial name
- NCT07421011
- Testing
- Trimedat®
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Valenta Pharm JSC
Irritable Bowel Syndrome-IBS
Evaluate the Safety of Linaclotide in IBS-C Patients in China
This is a Multi-center, single arm, observational study to evaluate the safety of linaclotide in IBS-C patients in China. Enrolls approximately 3,000 Chinese patients from 30 participating sites around China and followed up for…
- Trial name
- Liberty (NCT04462900)
- Where
- 29 sites in China
- Volunteers
- 3,028 people
- Sponsor
- AstraZeneca
Irritable Bowel Syndrome
EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth
Primary objective: to assess the efficacy of Bacillus clausii versus metronidazole in the eradication of the small intestinal bacterial overgrowth, 30 days after the end of treatment.
- Trial name
- NCT00331994
- Testing
- Bacillus clausii, Metronidazole
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Sanofi
Irritable Bowel Syndrome
Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome
The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX1031 versus a placebo control in subjects with non-constipating irritable bowel syndrome.
- Trial name
- NCT00813098
- Testing
- LX1031 High Dose, LX1031 Low Dose
- Where
- 36 sites in United States
- Volunteers
- 155 people
- Sponsor
- Lexicon Pharmaceuticals